Today’s fentanyl crisis: Prohibition’s Iron Law, revisited L Beletsky, CS Davis International Journal of Drug Policy 46, 156-159, 2017 | 212 | 2017 |
Association between medical cannabis laws and opioid overdose mortality has reversed over time CL Shover, CS Davis, SC Gordon, K Humphreys Proceedings of the National Academy of Sciences 116 (26), 12624-12626, 2019 | 211 | 2019 |
Opioid-overdose laws association with opioid use and overdose mortality C McClellan, BH Lambdin, MM Ali, R Mutter, CS Davis, E Wheeler, ... Addictive behaviors 86, 90-95, 2018 | 208 | 2018 |
Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts CS Davis, S Ruiz, P Glynn, G Picariello, AY Walley American journal of public health 104 (8), e7-e9, 2014 | 187 | 2014 |
Effects of an intensive street-level police intervention on syringe exchange program use in Philadelphia, PA. CS Davis, S Burris, J Kraut-Becher, KG Lynch, D Metzger American Journal of Public Health 95 (2), 233, 2005 | 181 | 2005 |
Legal changes to increase access to naloxone for opioid overdose reversal in the United States CS Davis, D Carr Drug and alcohol dependence 157, 112-120, 2015 | 175 | 2015 |
Laws limiting the prescribing or dispensing of opioids for acute pain in the United States: A national systematic legal review CS Davis, AJ Lieberman, H Hernandez-Delgado, C Suba Drug and alcohol dependence 194, 166-172, 2019 | 169 | 2019 |
State legal innovations to encourage naloxone dispensing C Davis, D Carr Journal of the American Pharmacists Association 57 (2), S180-S184, 2017 | 135 | 2017 |
Orienting patients to greater opioid safety: models of community pharmacy-based naloxone TC Green, EF Dauria, J Bratberg, CS Davis, AY Walley Harm reduction journal 12, 1-9, 2015 | 118 | 2015 |
State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies J Xu, CS Davis, M Cruz, P Lurie Drug and alcohol dependence 189, 37-41, 2018 | 113 | 2018 |
Engaging law enforcement in overdose reversal initiatives: authorization and liability for naloxone administration CS Davis, D Carr, JK Southwell, L Beletsky American journal of public health 105 (8), 1530-1537, 2015 | 102 | 2015 |
Emergency medical services naloxone access: a national systematic legal review CS Davis, JK Southwell, VR Niehaus, AY Walley, MW Dailey Academic Emergency Medicine 21 (10), 1173-1177, 2014 | 98 | 2014 |
Physician continuing education to reduce opioid misuse, abuse, and overdose: Many opportunities, few requirements CS Davis, D Carr Drug and alcohol dependence 163, 100-107, 2016 | 97 | 2016 |
Changing law from barrier to facilitator of opioid overdose prevention C Davis, D Webb, S Burris Journal of Law, Medicine & Ethics 41 (S1), 33-36, 2013 | 94 | 2013 |
The law (and politics) of safe injection facilities in the United States L Beletsky, CS Davis, E Anderson, S Burris American Journal of Public Health 98 (2), 2008 | 91 | 2008 |
Prescribe to prevent: overdose prevention and naloxone rescue kits for prescribers and pharmacists JK Lim, JP Bratberg, CS Davis, TC Green, AY Walley Journal of addiction medicine 10 (5), 300, 2016 | 87 | 2016 |
Association of pregnancy and insurance status with treatment access for opioid use disorder SW Patrick, MR Richards, WD Dupont, E McNeer, MB Buntin, PR Martin, ... JAMA network open 3 (8), e2013456-e2013456, 2020 | 84 | 2020 |
Opioid policy changes during the COVID-19 pandemic-and beyond CS Davis, EA Samuels Journal of Addiction Medicine, 2020 | 76 | 2020 |
Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19 CS Davis, EA Samuels International Journal of Drug Policy 93, 102905, 2021 | 73 | 2021 |
Association of Medicaid expansion with opioid overdose mortality in the United States N Kravitz-Wirtz, CS Davis, WR Ponicki, A Rivera-Aguirre, BDL Marshall, ... JAMA network open 3 (1), e1919066-e1919066, 2020 | 71 | 2020 |